Scarica l'app Stockscreener
16.47
0.78%
-0.13
Dopo l'orario di chiusura:
16.47
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Will Arcus Biosciences Inc. stock benefit from sector rotationWeekly Trend Recap & Short-Term Trading Alerts - Trung tâm Dự báo KTTV quốc gia
Applying sector rotation models to Arcus Biosciences Inc.Earnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Arcus Biosciences Hits Day High with Strong 8.19% Intraday Surge - Markets Mojo
Arcus Biosciences Hits Day High with 13.97% Surge Amid Market Decline - Markets Mojo
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets - Seeking Alpha
Arcus data throw TIGIT a lifeline: Clinical Report - biocentury.com
What dividend safety score for Arcus Biosciences Inc. stockMarket Sentiment Report & Entry Point Confirmation Alerts - newser.com
Why Arcus Biosciences Inc. stock is rated strong buyMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
Arcus’s ‘Last TIGIT Standing’ Shows Phase II Survival Benefit - insights.citeline.com
Arcus Biosciences reports Phase 2 survival data for gastric cancer study - Investing.com Canada
Arcus Biosciences Reports Promising Phase 2 Study Results - TipRanks
Arcus Biosciences reports Phase 2 survival data for gastric cancer study By Investing.com - Investing.com South Africa
Arcus Biosciences Announces Phase 2 Study Results - TradingView
Will Arcus Biosciences Inc. outperform the marketQuarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Visual analytics tools that track Arcus Biosciences Inc. performanceQuarterly Earnings Report & Weekly Consistent Profit Watchlists - newser.com
Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter
Arcus Biosciences (RCUS) Is Up 14.9% After Positive Phase 2 Survival Data in Gastric Cancer—What's Changed - Yahoo Finance
Citigroup Raises Price Target for RCUS to $54, Maintains Buy Rat - GuruFocus
Arcus Biosciences stock rises after strong gastric cancer survival data - Investing.com
Arcus Biosciences (RCUS) Shares Surge Following Positive Study R - GuruFocus
Arcus Biosciences rises on results from domvanalimab cancer study - Seeking Alpha
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga
What MACD signals say about Arcus Biosciences Inc.2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Sector Update: Health Care Stocks Higher Premarket Monday - MarketScreener
Arcus Biosciences (RCUS) Reveals Promising Phase 2 Gastric Cance - GuruFocus
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ - Stocktwits
Arcus Biosciences to present promising gastric cancer survival data - Investing.com
Arcus Bioscience announces first overall survival results from phase 2 edge-gastric study - MarketScreener
Arcus Biosciences Shows 26.7‑Month Median OS in EDGE‑Gastric | RCUS Stock News - Stock Titan
Price momentum metrics for Arcus Biosciences Inc. explainedWeekly Trend Summary & AI Driven Price Predictions - newser.com
Arcus Biosciences (NYSE:RCUS) COO Jennifer Jarrett Sells 37,792 Shares of Stock - MarketBeat
Arcus Biosciences Announces New Employment Inducement Grants - MarketScreener
60,300 Options at $15.05 — Arcus Biosciences Grants 30,150 RSUs under 2020 Inducement Plan - Stock Titan
Arcus Biosciences Hits Day High with Strong 7.27% Intraday Surge - Markets Mojo
Arcus Biosciences Hits Day High with Strong 8.46% Intraday Surge - Markets Mojo
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data By Investing.com - Investing.com Australia
Arcus Biosciences COO Jarrett sells $750k in shares By Investing.com - Investing.com Canada
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data - Investing.com India
Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? - MSN
Weiss Ratings Reaffirms "Sell (D-)" Rating for Arcus Biosciences (NYSE:RCUS) - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Arcus Biosciences stock By Investing.com - Investing.com Canada
RCUS: Truist Securities Raises Price Target for Arcus Biosciences | RCUS Stock News - GuruFocus
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment - inkl
A Fresh Look at Arcus Biosciences (RCUS) Valuation After New Casdatifan Data and Expanded Pipeline Initiatives - Yahoo Finance
Arcus Biosciences announces new anti-inflammation programs - BioWorld MedTech
Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating - MarketScreener
Arcus Biosciences Presents Promising ARC-20 Study Data - MSN
Why Is Arcus Biosciences Stock Trading Higher On Monday? - Sahm
Arcus Biosciences (NYSE:RCUS) Trading Up 15.2%Here's What Happened - MarketBeat
Transcript : Arcus Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Arcus Biosciences (RCUS) Sees Promising Results in Latest Study - GuruFocus
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):